Contextualizing adverse event following immunization data of coronavirus disease 2019 (COVID-19) vaccines in VigiAccess: An approach for reducing COVID-19 vaccine hesitancy

Peter Yamoah (pyamoah@gmail.com)
University of Health and Allied Sciences
https://orcid.org/0000-0001-6518-5454

Kofi Boamah Mensah
Kwame Nkrumah University of Science and Technology College of Health Sciences

Thelma Alalbila Mpoku
University of Health and Allied Sciences

Neelaveni Padayachee
University of the Witwatersrand

Frasia Oosthuizen
University of Kwazulu-Natal

Varsha Bangalee
University of Kwazulu-Natal

Research Article

Keywords: Adverse events following immunization, COVID-19 vaccines, pharmacovigilance, spontaneous reporting, VigiAccess

Posted Date: December 28th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1162779/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction

Vaccination features high among the public health interventions that have contributed significantly to global health. Following the March 2020 declaration by the World Health Organization that coronavirus 2019 (COVID-19) is a global pandemic, several vaccines have been developed and administered to curb the spread of COVID-19. One of the threats to attaining adequate vaccination uptake for these relatively new vaccines are concerns people have about the adverse event following immunization (AEFI) information. This study sought to assess AEFIs reported on COVID-19 vaccines approved for use so far in VigiAccess and to make a case for why AEFIs data in the database must be interpreted with caution.

Methods

The study followed a cross-sectional quantitative study design. VigiAccess was searched on November 10, 2021 for AEFIs reported so far for all the 12 approved COVID-19 vaccines. Data were captured among age groups, sex and continents of the world. Descriptive data were summarized using tables. Frequencies and percentages were used to categorize descriptive variables. No ethical approval was obtained before the commencement of the study as this was essentially a secondary data analysis of AEFI reports which cannot be linked to any individual. Consequently, there was no need for the informed consent process.

Results

Overall, 2,457,386 AEFIs had been reported in VigiAccess. AEFIs were found to be highest among the 18-44 age group (39.7%) and lowest in vaccine recipients below 12 years (0.1%). AEFIs were more common in females than male vaccine recipients with over two-thirds of the vaccine recipients being females. Among the continents of the world, AEFI reports were highest for Europe (50%) and lowest for Africa (3%). The top 10 commonly reported AEFI types were as follows: general disorders and vaccine administrative site conditions (1,481,549, 60.1%), nervous system disorders (1,046,928, 42.6%), musculoskeletal and connective tissue disorders (704,657, 28.6%), gastrointestinal disorders (495,997, 20.2%), investigations with undesirable outcomes (341,677, 13.9%), skin and subcutaneous tissue disorders (335,932, 13.6%), respiratory, thoracic and mediastinal disorders (262,158, 10.6%), infections and infestations (180,873, 7.3%), vascular disorders (132,533, 5.3%) and injury, poisoning and procedural complications (122,519, 5%).

Conclusion

The study showed that over 2 million COVID-19 AEFIs were spontaneously reported in VigiAccess, however, no causal relationships could be established between the vaccines and the AEFIs. The public accessing VigiAccess data should be made aware of this lack of association so that they may make well informed health decisions.
Introduction

Vaccination ranks high among the public health interventions that have contributed significantly to global health. Between the late 1800s and late 1900s, the leading causes of mortality were attributed to infectious diseases such as pneumonia, meningitis, influenza, tuberculosis, diphtheria, smallpox, pertussis, measles and typhoid fever [1]. However, the discovery and wide use of vaccines contributed significantly to the prevention of many untimely deaths resulting from infectious diseases, particularly in children. In the USA for instance, infectious disease data spanning the period of 1888 to 1924 showed that vaccines prevented approximately 40 million cases of diphtheria, 35 million cases of measles and a total of 103 million cases of childhood diseases [2]. Altogether, vaccines are estimated to prevent at least 6 million deaths, 400 million life years and 97 million disability adjusted life years every year [3].

Vaccines are tested in clinical trials for their safety and efficacy by drug regulatory agencies before approval for use in routine and mass vaccination campaigns. This notwithstanding, the safety of new vaccines is not completely understood from pre-authorization clinical trial data as these trials are conducted in controlled settings different from settings of real time use. Consequently, such data have limitations in their applicability in the wider population [4]. The reason for this limited applicability is as a result of the fact that during clinical trials of vaccines, dozens, hundreds and rarely thousands of participants receive vaccine doses as against millions of people who receive vaccine doses in routine and mass vaccination campaigns. Thus, there is a higher probability of real time vaccine recipients experiencing rare adverse events not recorded during clinical trials. In the wider population, some vaccine recipients may also respond differently to vaccines because of genetic variability, physiological and behavioural differences among other factors [5]. This particularly happens when the vaccines are manufactured and tested within a very short time frame as in the case of coronavirus disease 2019 (COVID-19) vaccines. Evidence from the Global Alliance for Vaccines and Immunizations (GAVI), the funding agency of most of the vaccines used in low and middle income countries (LMICs) for instance shows that the time frame between the introduction of new vaccines in developed countries and their subsequent use in LMICs has reduced considerably [6]. This reduction in time is an indication that safety data from developed countries where the vaccines were first launched may be insufficient at the time of introduction in LMICs necessitating intensive vigilance in the latter countries. Moreover, vaccine trials are conducted in a few days, months and rarely years and consequently, late occurring adverse event following immunizations (AEFIs) may not manifest within that short time frame as against many years of vaccine use in routine and mass vaccination campaigns [7]. Furthermore, the populations in which vaccines are introduced in clinical trials are fixed i.e. vaccines are mostly administered to either children, adolescents, pregnant women or the elderly alone versus the use of most vaccines across all populations in routine and mass vaccination campaigns [8]. As a result, there is the likelihood of some populations who were not represented during the clinical trial phase manifesting adverse events following the administration of vaccines in real time. For these reasons, vaccine surveillance must continue unabated following their marketing approval to ensure patient safety.
The COVID-19 which was declared by the World Health Organization (WHO) a global pandemic in March 2020 [9] has caused a lot of havoc. As of June 19, 2021, over 183 million confirmed cases and approximately 4 million deaths had been reported globally [10]. Following the March 2020 declaration by the WHO, several vaccines have been developed and administered to reduce COVID-19 spread. As of June 19, 2021, 78 candidate vaccines were being studied in clinical trials with 12 of them being approved on Emergency Use Authorization (EUA) basis by the WHO, United States Food and Drugs Administration (USFDA) and the European Medicines Agency (EMA) [11, 12].

Databases for reporting vaccine adverse events are very beneficial for understanding AEFIIs associated with COVID-19 vaccines. Two such important databases are Vigibase and VigiAccess. Whilst Vigibase has restricted access, VigiAccess is open to the public and can be accessed online. It is imperative that the public and the scientific community understand the implications of the COVID-19 AEFIIs recorded in VigiAccess in order not to exaggerate and misinform the general public about the data in the database. Following the initial COVID-19 pandemic declaration, the SARS-CoV-2 virus, the causative organism has undergone several mutations including Alpha, Beta, Gamma, Delta [13] and the most recent Omicron variant which had already been detected in 38 countries by December 3, 2021 [14–16]. Health experts believe that individuals who have been fully vaccinated against COVID-19 are less likely to suffer from severe illness and complications from this variant should they get infected. It is therefore important for a higher percentage of the general public to get vaccinated to reduce morbidity and mortality rates [17].

As more post-approval data are being collected to elucidate the efficacy of the newly developed vaccines in the larger population, their safety concerns must be investigated to enhance public trust and acceptability. Currently, there have been reports of COVID-19 vaccine hesitancy resulting from exaggeration of AEFIIs and myths propagated by conspiracy theorists [18, 19]. This study sought to assess AEFIIs reported on COVID-19 vaccines approved for use so far in VigiAccess and make a case for why AEFIIs data in the database must be applied with caution.

**Methodology**

The study followed a cross-sectional quantitative design. VigiAccess was searched on November 10, 2021 for AEFIIs reported to date among age groups, sex and continents of the world. Descriptive data were summarized using tables. Frequencies and percentages were used to categorize descriptive variables. No ethical approval was obtained before the commencement of the study as this was essentially a secondary data analysis of AEFI reports which cannot be linked to any individual. Consequently, there was no need for the informed consent process.

**Results**

After a thorough search of the database, it was observed that the AEFIIs were not matched with the individual COVID-19 vaccines but rather lumped together. Additionally, the AEFIIs were grouped based on
It was also observed that the AEFIs were classified based on systems-organ-class, generality and diseases and procedures occurring after vaccine administration.

**Age distribution**

Overall, 2,457,386 AEFIs had been reported in VigiAccess. AEFIs were highest among the 18-44 age group and lowest in vaccine recipients below 12 years. Table 1 describes the age distribution of vaccine recipients.

**Table 1: Age group distribution**

| Age group   | Frequency | Percentage |
|-------------|-----------|------------|
| Below 12 years | 3,585     | 0.1        |
| 12-17 years  | 39,049    | 1.6        |
| 18-44 years  | 974,453   | 39.7       |
| 45-64 years  | 758,305   | 30.9       |
| 65-74 years  | 155,930   | 6.3        |
| ≥75 years    | 232,113   | 9.4        |
| Unknown      | 293,951   | 12.0       |
| **Total**    | **2,457,386** | **100** |

**Sex distribution**

The results show that AEFIs were more common in females than male vaccine recipients with over two-thirds being females. Table 2 is a summary of AEFIs across male and female vaccine recipients.

**Table 2: Sex distribution**

| Sex     | Frequency | Percentage |
|---------|-----------|------------|
| Female  | 1,684,497 | 68.5       |
| Male    | 742,323   | 30.2       |
| Unknown | 30,566    | 1.3        |
| **Total** | **2,457,386** | **100** |
Continental distribution

Among the continents of the world, AEFI reports were highest for Europe and lowest for Africa. This is illustrated in table 3.

Table 3: Continental distribution of AEFI

| Continent | Frequency | Percentage |
|-----------|-----------|------------|
| Africa    | 69,441    | 3          |
| Americas  | 924,716   | 38         |
| Asia      | 156,966   | 6          |
| Europe    | 1,220,042 | 50         |
| Oceania   | 86,221    | 4          |
| Total     | 2,457,386 | 100        |

Commonly reported AEFIs

The top 10 commonly reported AEFI types were as follows: general disorders and vaccine administrative site conditions (1,481,549, 60.1%), nervous system disorders (1,046,928, 42.6%), musculoskeletal and connective tissue disorders (704,657, 28.6%), gastrointestinal disorders (495,997, 20.2%), investigations with undesirable outcomes (341,677, 13.9%), skin and subcutaneous tissue disorders (335,932, 13.6%), respiratory, thoracic and mediastinal disorders (262,158, 10.6%), infections and infestations (180,873, 7.3%), vascular disorders (132,533, 5.3%) and injury, poisoning and procedural complications (122,519, 5%). Moreover, the 10 most commonly reported AEFI manifestations were headache, pyrexia, fatigue, chills, myalgia, nausea, arthralgia, malaise, injection site pain and pain in extremity. Table 4 is a description of the top 5 manifestations of each of these top 10 AEFIs.

Table 4: Description of the top 10 AEFIs and their common manifestations
| AEFI types                                      | AEFI manifestation   | Frequency | Percentage |
|------------------------------------------------|----------------------|-----------|------------|
| General disorders and administrative site conditions | Pyrexia              | 513,460   | 20.9       |
|                                                | Fatigue              | 444,751   | 18.1       |
|                                                | Chills               | 342,918   | 14.0       |
|                                                | Malaise              | 211,303   | 8.6        |
|                                                | Injection site pain  | 179,959   | 7.3        |
| Nervous system disorders                       | Headache             | 636,476   | 25.9       |
|                                                | Dizziness            | 196,627   | 8.0        |
|                                                | Paraesthesia         | 74,004    | 3.0        |
|                                                | Hypoesthesia         | 50,845    | 2.1        |
|                                                | Syncope              | 38,076    | 1.5        |
| Musculoskeletal and connective tissue disorders | Myalgia              | 330,119   | 13.4       |
|                                                | Arthralgia           | 219,237   | 8.9        |
|                                                | Pain in extremity    | 175,673   | 7.1        |
|                                                | Back pain            | 38,907    | 1.6        |
|                                                | Limb discomfort      | 28,151    | 1.1        |
| Gastrointestinal disorders                     | Nausea               | 279,388   | 11.4       |
|                                                | Vomiting             | 88,655    | 3.6        |
|                                                | Diarrhoea            | 84,064    | 3.4        |
|                                                | Abdominal            | 37,552    | 1.5        |
|                                                | Upper abdominal pain | 24,849    | 1.0        |
| Investigations with undesirable outcomes       | Elevated blood pressure | 36,019   | 1.5        |
|                                                | Elevated heart rate  | 23,938    | 1.0        |
|                                                | Positive COVID-19 test | 20,491  | 0.8        |
|                                                | Reduced blood pressure | 4,882    | 0.2        |
|                                                | Weight loss          | 3,395     | 0.1        |
| Skin and subcutaneous tissue disorders         | Rash                 | 87,608    | 3.6        |
|                                                | Pruritus             | 75,647    | 3.1        |
| Disorder                                      | Count     | Prevalence |
|----------------------------------------------|-----------|------------|
| Hyperhidrosis                                | 52,261    | 2.1        |
| Erythema                                     | 45,127    | 1.8        |
| Urticaria                                    | 42,127    | 1.7        |
| **Respiratory, thoracic and mediastinal disorders** |           |            |
| Dyspnoea                                     | 100,081   | 4.1        |
| Cough                                        | 54,889    | 2.2        |
| Oropharyngeal pain                           | 34,203    | 1.4        |
| Rhinorrhoea                                  | 18,204    | 0.7        |
| Pulmonary embolism                           | 17,094    | 0.7        |
| **Infections and infestations**              |           |            |
| COVID-19                                     | 56,052    | 2.3        |
| Influenza                                    | 4,335     | 0.2        |
| Herpes zoster                                | 23,144    | 0.9        |
| Nasopharyngitis                              | 16,235    | 0.7        |
| Pneumonia                                    | 5,979     | 0.2        |
| **Vascular disorders**                       |           |            |
| Hypertension                                 | 23,678    | 1.0        |
| Flushing                                     | 13,635    | 0.6        |
| Hot flush                                    | 3,582     | 0.1        |
| Deep vein thrombosis                         | 12,049    | 0.5        |
| Hypotension                                  | 11,763    | 0.5        |
| **Injury, poisoning and procedural complications** |       |            |
| Inappropriate schedule of product administration | 15,367    | 0.6        |
| Contusion                                    | 13,081    | 0.5        |
| Fall                                         | 10,491    | 0.4        |
| Product storage error                        | 9,488     | 0.4        |
| Product administered to patient of inappropriate age | 8,944     | 0.4        |

**Discussion**

The present study was conducted to assess the adverse events associated with currently approved COVID-19 vaccines in the VigiAccess database. Globally, efforts are being made to increase the coverage of COVID-19 vaccines whilst generating more safety data on the vaccines so as to include children, adolescents and other special populations in vaccination schedules. For instance on November 2, 2021, the Centers for Disease Control and Prevention (CDC) recommended that children aged 5-11 years could
receive the Pfizer-Bio-NTech pediatric vaccine [20]. Hitherto, this age band was not included in COVID-19 vaccination schedules because of safety concerns.

Amid the rollout of COVID-19 vaccines in different countries, health officials and scientists have utilized national databases such as the Vaccine Adverse Event Reporting System (VAERS) database of USA to detect potential rare and unusual reactions to vaccines. Even though VigiAccess is a good open-access source of AEFI information for the general public, it is difficult to determine vaccine causality from the database as vaccine recipient details such as history of allergy to the vaccine ingredients, existing comorbidities, time of administration of vaccine to time of AEFI manifestation, etc which are typically recorded on individual case report form of vaccine recipients are unavailable in the database. Moreover, AEFI data in VigiAccess requires checks for duplicates and accuracy by health experts before causality assessment is carried out. On October 6, 2021, there were claims on social media by a section of the public/conspiracy theorists that COVID-19 vaccines are unsafe based on AEFI data in VigiAccess. This could have contributed to the COVID-19 vaccine hesitancy currently experienced in many parts of the world [21]. This calls for education and clarification on the utility of the database to allay fears and repose confidence in the COVID-19 vaccines.

The VigiAccess data revealed that half of all the AEFIs were reported from Europe whereas about two-fifths were reported from the Americas. Poor reporting of AEFIs from the African continent has been commonly observed in other studies [22–24]. Since spontaneous reports are beneficial in understanding the profile of AEFIs especially of newly approved vaccines, it is beneficial for all continents to actively get involved in AEFI reporting. One reason for the lower AEFI reporting rate for COVID-19 in Africa could be due to the lower and reduced COVID-19 vaccine uptake in Africa as compared to the rest of the world [25].

According to WHO, an AEFI is any untoward medical occurrence that may present after the administration of a vaccine but which does not necessarily have a causal relationship with the treatment, and this could be any unfavourable or unintended sign, abnormal laboratory finding, symptom or disease [26]. An AEFI could therefore be a vaccine related reaction like fever, rash, injection site pain, abscess and anaphylaxis among others which result from vaccine antigen and human antibody response and are usually temporal in nature [27]. The results show that the 10 most commonly reported AEFI manifestations were headache, pyrexia, fatigue, chills, myalgia, nausea, arthralgia, malaise, injection site pain and pain in extremity. Based on the definition of an AEFI, these may be self-limiting or temporal and therefore not a cause for alarm, however, if the vaccine product is suspected to have caused the event, then causality assessment taking into account other pre-vaccination and post-vaccination risk factors would have to be conducted. Alerting the public of this may strengthen the argument for pro-vaccination, whereby individuals can weigh the risk-benefit of self-limiting adverse events and the serious untoward effects of COVID-19.

AEFIs were commonly reported in females than males and in vaccine recipients aged 18-64 years. This finding is similar to that reported by the Centers for Disease Control and Prevention's (CDC's) Morbidity and Mortality Report (MMWR) in which both anaphylactic allergic and non-anaphylactic allergic reactions were reported after the first dose of the Pfizer Bio-NTech COVID-19 vaccine in women [28, 29]. The MMWR
report observed that majority of these women had a history of allergic reactions, however, this information cannot be verified in the VigiAccess database buttressing the reason not to draw conclusions on AEFI-vaccine relationship from data generated from the database. The increased incidence of AEFIs in women could be linked to the higher likelihood of women reporting these events as reported in previous studies [30, 31]. Another possible reason for the high number of AEFI reports in women than in men in VigiAccess could be due to the high vaccine hesitancy rate in men in comparison to women. A CDC report on June 22, 2021 for instance showed that nearly 9.5 million more women than men had been vaccinated in 42 states of the USA [32].

It is worth noting that AEFIs may also be associated with underlying medical conditions of vaccine recipients (coincidental effects), anxiety of vaccine recipient during vaccination, vaccine administration errors and vaccine quality defects [7]. Vaccine recipients with underlying medical conditions such as chronic hypertension, diabetes mellitus, asthma, etc need to inform health officials at vaccination centres for assessment to confirm their eligibility to receive the vaccines due to the possibility of the manifestation of coincidental AEFIs.

Moreover, an AEFI could be any unexpected event resulting from activities undertaken following an immunization, e.g. road traffic accident of a driver after receiving a vaccine dose. The exact cause of AEFIs such as the latter which may not be associated with the vaccine product is established via causality analyses. AEFI reporting is therefore a very significant component of vaccine pharmacovigilance because it helps to characterize AEFIs associated with specific vaccines for future reference through causality assessment [33]. The investigation could warrant the withdrawal of unwholesome vaccines or even contribute to the improvement in the quality of vaccines if safety is found to be associated with quality defects resulting from bad manufacturing practices. Moreover, healthcare professionals (HCPs) could improve vaccination practices such as injection techniques, storage and transportation of vaccines to maintain their quality when AEFIs are attributed to these factors [34, 35]. The reality of the achievement of global vaccine safety hinges on strengthening national pharmacovigilance systems and the commitment of other stakeholders especially HCPs who have been the major conduits of AEFI reporting.

Conclusions

The study showed that over 2 million COVID-19 AEFIs were spontaneously reported in VigiAccess out of which the 10 most commonly reported AEFI manifestations were headache, pyrexia, fatigue, chills, myalgia, nausea, arthralgia, malaise, injection site pain and pain in extremities. However, no causal relationships could be established between the vaccines and the AEFIs. It is imperative that countries actively engage in active primary vaccine safety studies such as cohort event monitoring to establish causality between AEFIs and vaccines. These findings could also be stored in open-access repositories for the general public, who equipped with the correct knowledge can make well informed health decisions.
Declarations

Funding information

The authors have no funding disclosure

Contributor information

Peter Yamoah, Email:pyamoah@uhas.edu.gh
Thelma Alalbila Mpoku, Email:talalbila@uhas.edu.gh
Kofi Boamah Mensah, Email:kofimensah227@yahoo.co.uk
Neelaveni Padayachee, Email: neelaveni.padaychee@wits.ac.za
Frasia Oosthuizen, Email:oosthuizenf@ukzn.ac.za
Varsha Bangalee, Email:bangalee@ukzn.ac.za

Conflict of Interest statement

The authors declare that there is no conflict of interest associated with this study.

Author Contributions

Substantial contributions to the conception or design of the work: PY, NP, VB, FO. Data mining from database: VB, TAM, KBM. Data analysis and interpretation: PY, FO, NP, TAM. Drafting the work or revising it critically for important intellectual content: PY, VB, FO. Proof reading: PY, TAM, NP, KBM. Final approval of the version to be published: PY, KBM, VB, TAM

References

1. Rappuoli R, Pizza M, Del Giudice G, et al. Vaccines, new opportunities for a new society. PNAS. 2014; 111(34): 12288–12293.
2. Murphy SL, Xu J, Kochanek KD. Deaths, Final data for 2010. NVSR. 2013; 61(4): 1–118.
3. World Health Organization. Immunization Safety Surveillance Guidelines for immunization programme managers on surveillance of adverse events following immunization; Second Edition, Geneva: World Health Organization Western pacific region. WHO, 2013.
4. Leite A, Andrews NJ, Thomas SL. Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods. Pharmacoepidemiol Drug Saf. 2016; 25(3): 225–237.
5. Whitaker JA, Ovsyannikova IG, Poland GA. Adversomics: a new paradigm for vaccine safety and design. Expert Rev. Vaccines. 2015; 14(7): 935–947.
6. Akanmori BD, Traore T, Balakrishnan M, et al. Vaccine Safety and Pharmacovigilance in the African Region: Recent Updates. J immunol sci. 2018; S (012):80-88.

7. Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015; 33(36):4398–4405.

8. Singh K, Mehta S. The clinical development process for a novel preventive vaccine: An overview. J Postgrad Med. 2016; 62(1):4–11.

9. Wetsman N, WHO declares the outbreak of the new coronavirus is a pandemic, March 11, 2020. https://www.theverge.com/2020/3/11/2/1156325/coronavirus-pandemic-who-declares-covid-19-outbreak-global-hini. Accessed: 25 Oct 2021.

10. Choudhary OP, Priyanka SI, Rodriguez-Morales AJ. Second wave of COVID-19 in India: dissection of the causes and lessons learnt. Travel Med Infect Dis. 2021; 43:102126.

11. Rabaan AA, Al-Ahmed SH, Sah R, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob. 2020; 19(1):40.

12. McGill COVID-19 Vaccine Tracker Team. 2021. Vaccines Candidates by Trial Phase. http://covid19.trackvaccines.org/vaccines/?fbclid=IwAR0rJdUx1T1j9Ta1YCJzwnqm6MW1uN2wwWtnuDPOGW6YvKLh3nW-ExOZKU. Accessed 15 Nov 2021.

13. Bakhshandeh B, Jahanafrooz Z, Abbasi A, et al. Mutations in SARS-CoV-2; Consequences in structure, function and pathogenicity of the virus. Microb Pathog. 2021; 154:104831.

14. Peterson E, Ntoumi F, Hui DS, et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)-highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2021.

15. Kimball S, WHO says COVID omicron detected in 38 countries, early data suggests it's more contagious than delta. https://www.cnbc.com/2021/12/03/who-says—omicron-covid-variant-has-spread-to-38-countries.html Accessed: 7 Dec 2021.

16. WHO 2nd Global consultation on assessing the impact of SARS-CoV-2 variants of concern on Public health interventions. https://www.who.int/publications/m/item/2nd-global-consultation-on-on-public-health-interventions Accessed: 2 Dec 2021.

17. Centers for Disease Control and Prevention, Omicron Variant: What you need to know. https://www.cdc.gov/coronavirus/2019-ncov/variant.html Accessed: 7 Dec 2021.

18. Danabal KGM, Magesh SS, Saravanan S, et al. Attitude towards COVID-19 vaccines and vaccine hesitancy in urban and rural communities in Tamil Nadu, India-a community based survey. BMC Health Serv Res. 2021; 21:994.

19. Dhama K, Sharun K, Tiwari R, et al. COVID-19 vaccine hesitancy-reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccin Immunother. 2021; 17(10):3495–3499.
20. Centers for Disease Control and Prevention, CDC Recommends Pediatric COVID-19 Vaccine for Children 5-11 Years. https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html Accessed: 7 Dec 2021.

21. USA Today, Fact check: Post misleads on WHO’s VigiAccess tool. https://www.usatoday.com/story/news/factcheck/2021/10/15/fact-check-post-misleads-whos-vigiaccess-tool/6101202001/ Accessed: 8 Dec 2021.

22. Gidudu JF, Shaum A, Dodoo A, et al, Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana. Vaccine. 2020; 38 (5):1009–1014.

23. Yamoah P, Bangalee V, Oosthuizen F. Knowledge and Perceptions of Adverse Events Following Immunization among Healthcare Professionals in Africa: A Case Study From Ghana. Vaccines. 2019; 7(1):28.

24. Centres for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Latest updates on the COVID-19 crises in Africa CDC; 2021. https://africacdc.org/covid-19/ Accessed: 11 Dec 2021.

25. Musuka JT, Khoza S. Adverse Events Following Immunization Reports from the Zimbabwe expanded programme on immunization (ZEPI) an analysis of spontaneous reports in Vigibase from 1997 to 2017. BMC Public Health. 2019; 19:1166.

26. Council for International Organizations of Medical Sciences, CIOMS. Definition and Application of Terms for Vaccine Pharmacovigilance, Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance, Geneva. 2012.

27. Cunha MP, Dórea JG, Marques RC, et al. Vaccine adverse events reported during the first ten years (1998-2008) after introduction in the state of Rondonia, Brazil. BioMed Res Int 2013; 853083.

28. Centers for Disease Control and Prevention. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine-United States, December 14-23, 2020 MMWR Morb Mortal Wkly Rep 2021. 2021; 70:46–51.

29. Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021; 325(8):780–781.

30. Joshi RK, Muralidharan CG, Gulati DS, et al. Higher incidence of reported adverse events following immunization (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. Med J Armed Forces India. 2021; 77 (Suppl 2); S505-S507.

31. Harris T, Nair J, Fediurek J et al, Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-2015. Vaccine. 2017;35 (19):2600–2604.

32. Puzio A, Why Is There Such A Gender Gap In COVID-19 Vaccination Rates? https://fivethirty.com/features/why-is-there-such-a-gender-gap-in-covid-19-vaccination-rates/ Accessed: 8 Dec 2021.

33. Parrella A, Gold M, Braunack-Mayer A, et al. Consumer reporting of adverse events following immunization (AEFI): Identifying predictors of reporting an AEFI. Hum Vaccin Immunother. 2014;10(3), 747–754.
34. Indian Society of Nephrology, Technical aspects of vaccine administration. Indian J Nephrol. 2016; 26(Suppl 1), S29–S30.

35. Kartoglu U, Milstien J. Tools and approaches to ensure quality of vaccines throughout the cold chain. Expert Rev Vaccines. 2014; 13(7), 843–854.